Abstract
Colorectal cancer (CRC) is one of the most prevalent malignancies in the world and developed drug resistance has represented one of the most challenging tasks for management. The current therapeutic regimens may select and enrich cancer stem-like cells (CSCs) resulting in the increased resistance against treatment, metastatic potential and mortality. Regorafenib is a multi-kinase inhibitor, an FDA-approved last-of-line treatment for patients with chemo-refractory metastatic CRC. However, regorafenib's potential effects on CSCs have not been fully elucidated. Here, we developed two 5-FU resistant CRC cell lines, HCT-116R and DLD-1R and showed the increased CSCs characteristics such as increased side-population cells, tumor sphere formation and expression of stemness markers. These cell lines and CSCs properties were used for evaluating the potential of regorafenib in suppressing CSCs. We showed that regorafenib treatment decreased the stemness phenotypes including tumor sphere formation, and side-population, of both HCT-116R and DLD-1R cells. Additionally, regorafenib suppressed the cell viability in both cell lines synergistically with 5-FU. In vivo, the combination of regorafenib and 5-FU significantly suppressed the tumorigen...Continue Reading
References
Sep 5, 2008·Current Protocols in Cytometry·Jordi Petriz
Dec 21, 2010·International Journal of Cancer. Journal International Du Cancer·Scott M WilhelmDieter Zopf
Jan 18, 2011·Nature Medicine·Can LiuDean G Tang
Sep 13, 2011·PloS One·Dara NallsSharmila Shankar
Oct 4, 2012·BMC Cancer·Go J YoshidaTatsuo Kuroda
Nov 28, 2012·Lancet·Axel GrotheyUNKNOWN CORRECT Study Group
Nov 15, 2013·Lancet·Hermann BrennerChristian Peter Pox
Dec 18, 2013·Biochemical and Biophysical Research Communications·Go J Yoshida, Hideyuki Saya
Feb 28, 2014·World Journal of Gastroenterology : WJG·Anna PryczyniczKatarzyna Guzińska-Ustymowicz
May 20, 2015·The Lancet Oncology·Jin LiUNKNOWN CONCUR Investigators
May 23, 2015·Drugs·Matt Shirley, Gillian M Keating
Aug 1, 2015·ELife·Jia LiUNKNOWN Reproducibility Project: Cancer Biology
Aug 5, 2015·Molecular Medicine Reports·Bin WeiXiao Gang Zhong
Sep 13, 2015·Cancer Science·Go J Yoshida, Hideyuki Saya
Sep 24, 2015·BMC Cancer·Tadeu Ferreira PaivaVladmir Cláudio Cordeiro de Lima
Mar 19, 2016·Oncotarget·Hung-Chih HsuTsai-Sheng Yang
Apr 16, 2016·Cancer Biology & Therapy·Hongyao ZhangYue Wang
May 5, 2016·American Journal of Therapeutics·Diana J MihalceaDragos Vinereanu
Jun 1, 2016·Oncotarget·Chia-Sing LuChao-Liang Wu
Jun 14, 2016·Scientific Reports·Yusuke NasuTakeaki Ozawa
Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lijun MaHongquan Zhang
Sep 1, 2016·Oncotarget·Li-Ching FanKuen-Feng Chen
Dec 30, 2016·Journal of Chemotherapy·Paola BertocchiAlberto Zaniboni
Dec 31, 2016·Molecular Medicine Reports·Chunyan LiBo Song
Feb 24, 2017·Cell Reports·Haiquan LuGregg L Semenza
Citations
Nov 13, 2018·Journal of Cellular Physiology·Masoud NajafiKeywan Mortezaee
Sep 11, 2019·Cell Death & Disease·Baochi OuAiguo Lu
Dec 19, 2018·Journal of Experimental & Clinical Cancer Research : CR·Maria Elena PisanuRita Mancini
Sep 26, 2019·Experimental & Molecular Medicine·Flavia FondevilaJosé L Mauriz
Feb 6, 2020·Oncotarget·Cristiano FaraceRoberto Madeddu
Mar 13, 2020·International Journal of Cancer. Journal International Du Cancer·Sarun JuengpanichXiujun Cai
Jun 27, 2020·Cancer Biology & Therapy·Chunhua ZhouLulu Zhai
Sep 20, 2018·International Journal of Molecular Sciences·Lei DingQinghua Cui
Feb 12, 2021·Pharmaceuticals·Eunsun JungTae-Su Han
Nov 25, 2020·Cancers·Andrea PisanoRoberto Madeddu
Feb 11, 2021·International Journal of Molecular Sciences·Andrea AngiusMaria Rosaria De Miglio
Feb 17, 2021·Signal Transduction and Targeted Therapy·He-Ming ZhouQin Li
Mar 20, 2021·Seminars in Cancer Biology·Rui ZhangSuling Liu
Apr 4, 2021·Biomedicines·Valentina AngerilliMatteo Fassan
May 1, 2021·Cancers·Elisa CondeAlfredo Carrato